The Cheapest Way to Get Mounjaro: 6 Real Options, Ranked

The cheapest way to get Mounjaro right now, ranked

Line up every real path to Mounjaro side by side and the spread is enormous — from nothing at all to well over a thousand dollars a month for the identical drug. Which end you land on has almost nothing to do with luck and almost everything to do with three facts about your own situation: whether you carry commercial insurance, whether that plan happens to cover Mounjaro specifically, and whether the prescription in front of you is written for type 2 diabetes or for weight management.

• Lilly Cares Foundation — free, if you qualify. Uninsured, documented type 2 diabetes, household income under roughly $63,840/yr for one person. Worth checking before shopping anything else on this list.
• Lilly Savings Card, insured and covered — $25/mo. Your commercial plan already covers Mounjaro for diabetes; the card just knocks the copay down.
• Compounded tirzepatide — ~$199 to $449/mo. No insurance required at all; Curex's roughly $199 starter rate is the lowest we could verify.
• LillyDirect Zepbound self-pay — $299 to $449/mo. Real, FDA-approved tirzepatide, sold under the weight-management brand rather than Mounjaro.
• Lilly Savings Card, insured but not covered — $499/mo. Still a steep discount off retail, just a much smaller one than the $25 tier.
• Retail or GoodRx, no program — $1,020 to $1,150/mo. The number almost nobody reading this should end up paying.

If insurance covers Mounjaro, the Lilly Savings Card is hard to beat

For a specific slice of patients, this is genuinely the end of the search. If your commercial insurance plan already has Mounjaro on formulary for type 2 diabetes, and your prescriber's documentation matches that FDA-approved indication, the Lilly Savings Card can bring your monthly cost to $25. That works out to $1,950 for a full year, the cap Lilly has set on the card through the end of 2026.

The catch sits in that middle clause: the prescription has to match the label. Mounjaro is approved for type 2 diabetes only, so a chart that documents weight management instead — even for a patient who also happens to have diabetes — can knock you out of this tier. It's also worth knowing this card doesn't help everyone who's insured. Medicare, Medicaid, TRICARE, and other government programs are excluded outright, no exceptions.

Trying to lose weight, not manage diabetes? Zepbound is the real cheap option

One surprise trips up almost every shopper who lands on this page looking for a cheap self-pay Mounjaro option: Eli Lilly never built a direct-to-patient cash program under the Mounjaro name at all. The company's actual self-pay infrastructure exists only under Zepbound, the sister brand approved for chronic weight management rather than diabetes. Mounjaro and Zepbound share the same active ingredient, tirzepatide, made by the same manufacturer at the same dose strengths — the only real difference is which FDA approval sits on top of each name.

Because most people chasing a cheap tirzepatide price are actually using it off-label for weight loss, Zepbound is the brand that matters here. Through LillyDirect, self-pay vials run $299 a month at the 2.5mg starting dose, $399 at 5mg, and $449 from 7.5mg through 15mg — provided your next order goes out within 45 days of your last delivery. Miss that window and the discounted rate resets: $499 a month at 7.5mg, and $699 a month from 10mg through 15mg, based on the most recent pricing we could confirm.

If your prescriber is open to either brand and weight management is genuinely the goal, this is very likely the cheaper honest path — cheaper than chasing a Mounjaro discount that structurally doesn't exist. See Mounjaro without insurance for the complete self-pay breakdown by situation.

Mounjaro has no self-pay vial program — here's what uninsured patients actually pay

If your prescription genuinely is for type 2 diabetes and you have no insurance at all, the Lilly Cares Foundation route below is worth checking first. Short of that, uninsured patients paying for the Mounjaro brand specifically are looking at full retail — there's no discounted cash-pay ladder for this brand the way there is for Zepbound. That means the $1,020 to $1,150 a month figure further down this page is the real number, not a worst-case scenario.

It's also worth understanding why insurance denies Mounjaro in the first place, since that shapes whether appealing is worth your time. Coverage runs off the diagnosis code submitted with the claim, not off the drug itself — a plan can pay generously for Mounjaro when the chart says type 2 diabetes and deny the identical prescription when the documented reason is weight management. If you have a genuine diabetes diagnosis and were coded incorrectly, that's often a fixable clerical issue rather than a real denial.

Is compounded tirzepatide cheaper — and still legal?

Cheaper, yes. Legal, only under a narrower set of conditions than during the shortage years. The FDA declared the tirzepatide shortage resolved in October 2024, which phased out the broad compounding that let 503B outsourcing facilities produce tirzepatide copies at scale without a patient-specific prescription; that pathway wound down by March 2025. What remains is the 503A route: a state-licensed pharmacy compounding tirzepatide for one named patient, when a prescriber documents a real clinical reason the commercial product won't work — an allergy to an inactive ingredient, for example. Cost alone doesn't count as that reason under current FDA guidance, even though cost is why most people end up here.

Among the providers we checked, Curex holds the lowest all-in starter price at roughly $199 a month, covering medication, the online consult, and shipping with no separate membership fee — though that's a starter-dose rate, so ask for the full maintenance-dose price before enrolling. Mochi Health prices medication at a flat $199 a month but adds a separate $79-a-month membership billed as its own subscription, for a real all-in cost near $278. Henry Meds runs $349 for its oral tablet and $449 for the injectable version, bundled with no extra membership fee.

The legal landscape around these providers has also been moving. Eli Lilly sued four telehealth companies — Mochi Health, Willow, Henry Meds, and Fella Health — in April 2025 over how they marketed compounded tirzepatide. A federal judge dismissed the case against Willow in September 2025, finding Lilly hadn't shown patients had actually switched away from its branded products. Lilly's case against Mochi Health was narrowed on an earlier motion, then an amended version was allowed to proceed in April 2026 on unfair-competition and trademark grounds. Henry Meds and Fella Health's cases were still active as of the most recent reporting we found — worth a fresh check before you enroll anywhere, since telehealth litigation in this space moves quickly.

There's also a pending regulatory question sitting above all of this: on April 30, 2026, the FDA proposed removing tirzepatide, along with semaglutide and liraglutide, from the 503B bulk drug substances list entirely. The public comment period, extended once already, closed on July 30, 2026, and no final rule had been issued as of this writing. That proposal targets large-scale 503B bulk compounding specifically, which has already wound down in practice — it doesn't touch the 503A individual-patient pathway the providers above rely on.

Does GoodRx actually beat these prices?

Not by much, which surprises people used to GoodRx cutting other drugs' prices sharply. Full retail for a 28-day carton of Mounjaro, any dose, runs roughly $1,020 to $1,150 a month, and a GoodRx coupon tends to land within that same band rather than meaningfully under it. Lilly's own pricing agreements with pharmacy benefit managers limit how deep a third-party discount card can cut, so there isn't much room left for GoodRx to work with on this particular drug.

Pharmacy-to-pharmacy variation is real, though — some retail chains have been reported running noticeably above that $1,150 ceiling, so it's worth checking a live price by ZIP code before you fill anywhere. Even at the best price you find, though, you're still paying several times what compounded tirzepatide or LillyDirect's Zepbound self-pay program charges for the same molecule, which is the comparison that actually matters if cost is the deciding factor.

Can you get Mounjaro completely free? Lilly Cares Foundation

Yes, for a specific group of patients. Lilly Cares Foundation, Eli Lilly's charitable patient-assistance program, can provide Mounjaro at no cost to uninsured patients with an active type 2 diabetes prescription and household income at or below roughly 400% of the federal poverty level. For a single person, that threshold sits at $63,840 a year under the federal poverty guidelines that took effect in January 2026 — a number that's worth double-checking directly at lillycares.com, since it adjusts annually and different sources sometimes cite a slightly older figure.

This program is built around Mounjaro's diabetes indication, not around Zepbound or weight management, so if your prescription is written for weight loss rather than diabetes, it's unlikely to be your path — the compounded or LillyDirect routes above are the more realistic options for that situation. Processing time for a complete application is reported anywhere from about one to four weeks, so it's worth applying with every document in hand the first time rather than in stages.

What a full year actually costs, tier by tier

• Lilly Cares Foundation, if eligible: $0/year
• Lilly Savings Card, insured and covered: ~$300/year ($25 x 12, well under the $1,950 annual cap)
• Compounded tirzepatide (Curex, starter rate): ~$2,388/year ($199 x 12)
• Compounded tirzepatide (higher-tier provider): ~$5,388/year ($449 x 12)
• LillyDirect Zepbound, starting dose: ~$3,588/year ($299 x 12)
• LillyDirect Zepbound, maintenance dose: ~$5,388/year ($449 x 12)
• Lilly Savings Card, insured but not covered: ~$5,988/year ($499 x 12)
• Retail, no program at all: ~$12,240–$13,800/year ($1,020–$1,150 x 12)

The distance between the cheapest realistic path and full retail runs past $12,000 a year in the most common scenarios. Almost none of that gap comes down to finding a better coupon — it comes down to knowing which tier you actually qualify for before you fill anything.

Red flags to watch for when chasing the cheapest tirzepatide price

Chasing the lowest possible price on tirzepatide has pulled outright scammers into the same search results as legitimate providers, so a few checks are worth running no matter which option on this page looks most appealing.

• Walk away from any seller that doesn't require a real prescription or clinician evaluation — that's not legal, and it's a genuine counterfeit and dosing-error risk.
• Watch for 'tirzepatide sodium' or 'tirzepatide acetate' on a label or product page — the FDA has stated it isn't aware of a lawful basis for compounding these unapproved salt forms, and they aren't proven equivalent to the tirzepatide in Mounjaro or Zepbound.
• Be cautious of any compounding provider that won't name the specific licensed pharmacy filling your prescription if you ask directly.
• Treat any price dramatically below every figure on this page, with no explanation for how it's possible, as a sign you're not looking at a real product.
• If a provider markets cost savings itself as the medical justification for compounding, that's the opposite of what the current FDA pathway actually requires.